REMARKS

Applicants have amended the claims in order to reduce the initial filing fee by deleting the improper use claim 18 and by deleting the multiple dependent claims from the application. Applicants retain the right to reintroduce any subject matter canceled by the present Amendment at any time during the prosecution of this application or any further application claiming benefit of this application. Also, an Abstract of the Disclosure has been added to the application.

Applicants are submitting herewith a copy of the Search Report which issued on International Application No. PCT/GB00/01813, of which the present application is the U.S. national phase. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449. It is Applicants' understanding that, under the procedures of the PCT, copies of the cited publications will have been supplied to the U.S. Patent Office by the International Bureau. However, the Examiner is invited to contact the undersigned attorney if additional copies are necessary or would facilitate examination of the present application.

Otherwise, the Examiner is respectfully requested to return an initialed and dated copy of the attached Form PTO-1449 to confirm that all publications listed thereon have been considered and made officially of record in the file of this application.

Applicants understand that, under the procedures of the PCT, a copy of the priority document (9910934.0, filed 11 May 1999) will have been supplied to the U.S. Patent Office pursuant to Rule 17 of the PCT Regulations. It is therefore respectfully requested that the first Official Action in the present application contain an indication that the appropriate priority document is in the file of this application.

In view of the above amendments, an early action on the application is now in order and is most respectfully requested.

Respectfully submitted,
BACON & THOMAS, PLLC

By: Richard E. Fichter
RICHARD E. FICHTER
Registration No. 26,382

625 Slaters Lane - 4th Floor
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:kdd
PA01.wpd

DATE: November 13, 2001

Marked-Up Version Showing Changes Made

IN THE CLAIMS:

Please replace claims 5, 8-9, 11, 13, 17 and 19-20 with the following amended claims.

5(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein R^4 a hydrogen atom, a silyl group, a C_{1-6} alkyl group optionally interrupted by one or more oxygen atoms or substituted by a lower cycloalkyl group, a cyclic ether group, a C_{1-6} alkanoyl group, an aroyl group, a C_{1-6} alkane sulphonyl or halogenated methane sulphonyl group, or an arene sulphonyl group.

8(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein R^5 represents a hydrogen atom or a methoxy group.

9(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein X represents a hydroxyl group or a group of formula NR^6R^7 wherein:

R^6 is a C_{1-6} alkyl group, C_{6-12} carbocyclic aryl C_{1-4} alkyl group, C_{1-6} alkanoyl group, C_{6-12} carbocyclic aryl C_{2-5} alkanoyl group, C_{7-13} carbocyclic aroyl group or any of the preceding groups substituted by one or more halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkylamino, di (C_{1-4} alkyl) amino, nitro, carbamoyl or C_{1-4} alkanoylamino substituents; and

R^7 is a hydrogen atom or a C1-6 alkyl group.

11(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein Y contains up to 7 carbon atoms and up to 3 multiple bonds.

13(Amended). Compounds of formula (I) as claimed in [any of the preceding claims] claim 1 wherein Y is substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group positioned α-, β- or γ- to the group -C(R^1) (R^2), X or α- to any triple bond present in the group Y.

17(Amended). Active compound of formula (I) as claimed in [any preceding claim] claim 1 for use in management of neoplastic disease; as agents to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathyroidism, asthma, cognitive impairment or senile dementia; in fertility control in either human or animal subjects; in management of disorders involving blood clotting; or in reduction of serum cholesterol.

19(Amended). Pharmaceutical compositions comprising an active compound of formula (I) as claimed in [any one of claims 1 to 16] claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

20(Amended). A method of treatment of a human or animal subject in the management of neoplastic disease; to promote wound healing; in burn management; in treatment of bone diseases, autoimmune disease, host-graft reaction, transplant rejection, inflammatory diseases, neoplasias or hyperplasias, myopathy, enteropathy or spondylitic heart disease; in suppression of parathyroid hormone; in treatment of dermatological diseases, hypertension, rheumatoid arthritis, psoriatic arthritis, secondary hyperparathryoidism, asthma, cognitive impairment or senile dementia; in fertility control; in management of disorders involving blood clotting; or in reduction of serum cholesterol, which method comprises administering to said subject a

therapeutically effective amount of an active compound of formula (I) as claimed in [any of claim s 1 to 16] claim 1.